R&D Pipeline
Guided by innovation and internationalization, Fosun Pharma increases its investment in R&D and the introduction of scientific research personnel, enriches its innovative product pipelines, improves its R&D and clinical trial capacities for new drugs, and speeds up the R&D and transformation of innovative technologies and products through diverse and multi-level cooperation models, such as independent R&D, co-development, in-licensing, and in-depth incubation.
Major Drugs under Development
As of December 2023, Fosun Pharma has 70+ major innovative drugs and biosimilars under development (calculated by indication).
-
- 20
- Self-developed small molecule innovator drug
-
- 25
- Self-developed innovative biologics
-
- 20
- In-licensing innovator drugs
-
- 10
- Self-developed biosimilars